Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GenSight Biologics S.A.

http://www.gensight-biologics.com/

Latest From GenSight Biologics S.A.

Renamed Coave Therapeutics Raises $39m To Fund Its Next-Gen Gene Therapies

The company aims to overcome drawbacks of existing gene therapy platforms, starting in ocular and CNS diseases.

Commercial Companies

Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.

Europe Approvals

EU Review Gets Under Way For Curative Vision Loss Gene Therapy

GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.

Ophthalmic Review Pathway

Seeing Is Believing: New Approaches For Treating Eye Disorders

Developers of new ophthalmic products are thinking outside of the box. A raft of new gene therapies are progressing in the clinic, including a gene therapy paired with biomimetic goggles. Elsewhere, technology players are partnering with traditional biopharmaceutical companies and bringing algorithms, machine learning and microelectronics to bear on eye disorders and disease diagnostics.

Biologics Gene Therapy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register